PMID- 37017716
OWN - NLM
STAT- MEDLINE
DCOM- 20230407
LR  - 20230420
IS  - 1473-6519 (Electronic)
IS  - 1363-1950 (Linking)
VI  - 26
IP  - 3
DP  - 2023 May 1
TI  - Linoleic acid, an omega-6 fatty acid that reduces risk for cardiometabolic 
      diseases: premise, promise and practical implications.
PG  - 288-292
LID - 10.1097/MCO.0000000000000919 [doi]
AB  - PURPOSE OF REVIEW: As heart disease and type 2 diabetes mellitus (T2DM) cases 
      continue to rise, identifying lifestyle modifications to prevent cardiometabolic 
      disease (CMD) is urgently needed. Clinical evidence consistently shows that 
      higher dietary or biomarker levels of linoleic acid (LA; 18:2n6) reduce metabolic 
      syndrome (Mets) and reduce the risk for CMD. Yet, dietary recommendations to 
      include LA as part of a lifestyle plan with the goal of preventing CMD remain 
      elusive. RECENT FINDINGS: Clinical interventions consistently show that dietary 
      the addition of LA to the diet improves body composition, dyslipidemia, and 
      insulin sensitivity while reducing systemic inflammation and fatty liver. These 
      effects of LA position dietary LA-rich oils as a potential dietary strategy to 
      aid in preventing CMD. Peroxisome proliferator-activated receptors (PPARs) are 
      nuclear hormone receptors that are cellular targets for many polyunsaturated 
      fatty acids and oxylipin metabolites. PPAR activation can regulate dyslipidemia, 
      insulin sensitivity, adipose biology, and inflammation, potentially explaining 
      the plethora of effects of dietary LA on aspects of CMD. SUMMARY: Unraveling the 
      cellular mechanism(s) of LA to impact PPAR activity may reset a false dogma that 
      LA, as a member of the omega-6 fatty acid family, promotes inflammation in 
      humans. In fact, LA appears to reduce inflammation and reduce risk for CMD.
CI  - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Belury, Martha Ann
AU  - Belury MA
AD  - Human Nutrition Program in the Department of Human Sciences, The Ohio State 
      University, Columbus, Ohio, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230302
PL  - England
TA  - Curr Opin Clin Nutr Metab Care
JT  - Current opinion in clinical nutrition and metabolic care
JID - 9804399
RN  - 9KJL21T0QJ (Linoleic Acid)
RN  - 0 (Fatty Acids, Omega-6)
RN  - 0 (Peroxisome Proliferator-Activated Receptors)
SB  - IM
MH  - Humans
MH  - Linoleic Acid
MH  - *Insulin Resistance
MH  - Fatty Acids, Omega-6
MH  - *Diabetes Mellitus, Type 2
MH  - Peroxisome Proliferator-Activated Receptors
MH  - Inflammation
MH  - *Cardiovascular Diseases/prevention & control
EDAT- 2023/04/06 06:00
MHDA- 2023/04/07 06:41
CRDT- 2023/04/05 11:13
PHST- 2023/04/07 06:41 [medline]
PHST- 2023/04/05 11:13 [entrez]
PHST- 2023/04/06 06:00 [pubmed]
AID - 00075197-202305000-00015 [pii]
AID - 10.1097/MCO.0000000000000919 [doi]
PST - ppublish
SO  - Curr Opin Clin Nutr Metab Care. 2023 May 1;26(3):288-292. doi: 
      10.1097/MCO.0000000000000919. Epub 2023 Mar 2.